FREQUENCY AND ASSOCIATION OF 1691 (G>A) FVL,
20210 (G>A) PT AND 677 (C>T) MTHFR WITH
DEEP VEIN THROMBOSIS IN THE POPULATION
OF BOSNIA AND HERZEGOVINA Jusić-Karić A, Terzić R, Jerkić Z, Avdić A, Pođanin M *Corresponding Author: Amela Jusić-Karić, Ph.D., Faculty of Science and Mathematics, University of Tuzla,
Univerzitetska 4, 75 000 Tuzla, Bosnia and Herzegovina. Tel: +387-61-289-217. Fax: +387-35-320-861.
E-mail: amela.jusic @untz.ba page: 43
|
REFERENCES
1. Miletich JP, Prescott SM, White R, Majerus PW,
Bovill EG. Inherited predisposition to thrombosis.
Cell. 1993; 72(4): 477-480.
2. Alfirevic Z, Simundic AM, Nikolac N, Sobocan
N, Alfirevic I, Stefanovic M, et al. Frequency of
factor II G20210A, factor V Leiden, MTHFR
C677T and PAI-1 5G/4G polymorphism in patients
with venous thromboembolism: Croatian
case control study. Biochemia Medica. 2010;
20(2): 229-235.
3. Segers K, Dahlback B, Gerry AFN. Coagulation
factor V and thrombophilia: Background and
mechanisms. Thromb Haemost. 2007; 98(3):
530-542.
4. Katcharin A, Napaporn A, Timaluck S, Pantep
A. Prevalence of factor V Leiden (G1691A) and
prothrombin gene mutation (G20210A) among
different ethnic group in Thai hospitals. J Hematol
Transfus Med. 2012; 22(2): 115-120.
5. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma
PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein
C). Blood. 1995; 85(6): 1504-1508.
6. Ridker PM, Miletich JP, Hennekens CH, Buring
JE. Ethnic distribution of factor V Leiden in 4047
men and women. Implications for venous thromboembolism
screening. JAMA. 1997; 277(16):
1305-1307.
7. Herrmann FH, Koesling M, Schrŏder W, Altman
R, Jiménez Bonilla R, Lopaciuk S, et al.
Prevalence of factor V Leiden mutation in various
population. Genet Epidemiol. 1997; 14(4):
403-411.
8. Poort SR, Rosendaal FR, Reitsma PH, Bertina
RM. A common genetic variation in the 3’-untranslated
region of the prothrombin gene is
associated with elevated plasma prothrombin
levels and an increase in venous thrombosis.
Blood. 1996; 88(10): 3698-3703.
9. Bavikatty N, Kileen A, Akel N, Normolle D,
Schmaier A. Association of the prothrombin
G20210A mutation with factor V Leiden in a
midwestern American population. Am J Clin
Pathol. 2000; 114(2): 272-275.
10. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero
F. The VITA project: C677T mutation in the
methylene-tetrahydofolate reductase gene and
risk of venous throm-boembolism. Br J Haematol.
1997; 97(4): 804-806.
11. den Heijer M, Lewington S, Clarke R. Homocysteine,
MTHFR and risk of venous thrombosis.
N Engl J Med. 2005; 3(2): 292-299.
12. Karic A, Terzic R, Jerkic Z, Mustedanagic-Mujanovic
J. The frequency of C677T methylentetrahidrofolate
reductase (MTHFR) polymorphism
in Southern East Bosnian population. J Biomet
Biostat. 2013; 4(4): 1-4.
13. Adler G, Agnieszka G, Valjevac A, Czerska
E, Kiseljaković E, Salkic N. Prevalence of genetic
prothrombotic risk factors: 1691G>A FV,
20210G>A PT and 677 C>T MTHFR mutations
in Bosnian population. Ann Hum Biol. 2014;
42(6): 576-580.
14. Bertina RM, Koelman BP, Koster T, Rosendaal
FR, Dirven RJ, de Ronde H, et al. Mutation in
blood coagulation facto V associated with resistance
to activated protein C. Nature. 1996;
369(6475): 64-67.
15. Froost P, Blom HJ, Milos R, Gazette P, Sheppard
CA, Matthews RG, et al. A candidate genetic
risk factor for vascular disease: A common mutation
in methylene-tetrahydrofolatereductase.
Nat Genet. 1995; 10(1): 111-113.
16. McHugh M. The odds ratio: Calculation, usage
and inerpretation. Biochemia Medica. 2009;
19(2): 120-126.
17. Kejzer M, den Hajer M, Blom HJ, Bos GMJ, Willems
HPJ, Gerrits WBJ, et al. Interaction between
hyperhomocysteinemia, mutated methylenetetrahydro-
folate reductase (MTHFR) and inherited
thrombophilic factors in recurrent venous thrombosis.
Thromb Haemost. 2002; 88(5): 72-78.
18. Meglic L, Stegnar M, Milanez T, Bozic M,
Peterlin B, Peternel P, et al. Factor V Leiden,
prothrombin 20210 G>A, methylenetetrahydrofolate
reductase 677C>T and plasminogen activator
inhibitor 4G/5G polymorphism in women
with pregnancy related venous thromboembolism.
Eur J Obstet Gynecol Reprod Biol. 2003;
111(2): 157-163.
19. Berge E, Haug KB, Sandset EC, Haughbro KK,
Turkovic M, Sandset PM. The factor V Leiden,
prothrombin gene 20210GA, methylenetetrahydrofolate
reductase 677CT and platelet glycoprotein
IIIa 1565TC mutations in patients
with acute ishemic stroke and atrial fibrillation.
Stroke. 2007; 38(3): 106-171.
20. Pauer H, Voigt-Tschirschwitz T, Hinney B, Burfeind
P, Wolf C, Emons G, et al. Analyzes of
three common thrombophilic gene mutations in
German women with recurrent abortions. Acta
Obstet Gynecol Scand. 2003; 82(10): 942-947.
21. Koster T, Roosendal FR, de Ronde H, Riet E,
Vandenbroucke JP, Bertina R. Venous thrombosis
due to poor anticoagulant response to activated
protein C: Leiden thrombophilila study.
Lancet. 1993; 342(8886-8887): 1503-1506.
22. Coen D, Zadro R, Honović, Banfic Lj, Rukavina-
Stavljenic A. Prevalence and association of the
factor V Leiden and prothrombin G20210A in
healthy subjects and patients with venous thromboembolism.
Croat Med J. 2001; 42(4): 488-492.
23. Đorđevic V, Rakicevic Lj, Mikovic D, Kovac
M, Miljic P, Radojkovic D, et al. Prevalence
of factor V Leiden, factor V Cambridge, factor II G20210A and meth-ylenetetrahydrofolatereductase
C677T mutations in healthy and thrombophilic
Serbian populations. Acta Haematol.
2004; 112(4): 227-229.
24. Arsov T, Miladinova D, Spiroski M. Factor V
Leiden is associated with higher risk deep venous
thrombosis of large blood vessels. Croat
Med J. 2006; 47(3): 433-439.
25. Jadaon MM. Epidemiology of prothrombin
G20210A mutation in the Mediterranean region.
Mediterr J Hematol Infect Dis. 2011; 3(1):
e2011054. doi: 10.4084/ MJHID.2011.054.
26. Isotalo PA, Donnely JG. Prevalence of methylene-
tetrahydrofolatereductase mutations in
patients with venous thrombosis. Mol Diagn.
2000; 5(1): 59-66.
27. Moglinicka-Nizankowska E, Adamek L, Grzanka
P, Domagala TB, Sanak M, Krzanowski M, et al.
Genetic polymorphisms associated with acute
pulmonary embolism and deep venous thrombosis.
Eur Respir J. 2003; 21(1): 25-30.
28. D’Angelo A, Beltramentti C. Venous disease.
In: Carmel R, Jacobsen DW, Eds. Homocysteine
in Health and Disease. Cambridge, Cambridgeshire,
UK: Cambridge University Press.
2001:401-414.
29. Tsai AW, Cushman M, Tsai MY, Heckbert SR,
Rosamond WD, Aleksic N, et al. Serum homocysteine,
thermolabile variant of methylenetetrahydrofolat
reductase (MTHFR) and venous
thromboembolism: Longitudinal investigation
of thromboembolism etiology (LITE). Am J Hematol.
2003; 72(3): 192-200.
30. Beyan C, Beyan E. MTHFR 677 CT gene polymorphism
is not a risk factor for venous thromboembolism.
Çukurova Med J. 2014; 39(1):
189-190.
31. Ehrenforth S, von Fepka-Prondsinski M, Aygoren-
Pursun E, Nowak-Gottl U, Scharrer I, Ganser
A. Study of the prothrombin gene 20210GA
variant in FV:Q506 car-riers in the relationship
to the presence or absence of juvenile venous
thromboemolism. Arterioscler Thromb Vasc
Biol. 1999; 19(2): 276-280.
32. Zoller B, Svanson PJ, He X, Dahlback B. Identification
of the same factor V gene mutation
in 47 out of 50 thrombosis-prone families with
inherited resistance to activated protein C. J Clin
Invest. 1994; 94(6): 2521-2524.
33. Ferraresi P, Marchetti G, Legnani C, Cavallari E,
Castoldi E, Mascoli F, et al. The heterozygous
20210G/A prothrombin genotype is associated
with early venous thrombosis in inherited thrombophilia
and is not increased in frequency of
artery disease. Arterioscler Thromb Vasc Biol.
1997; 17(11): 2418-2422.
34. De Stefano V, Martinelli I, Mannuccio P, Paciaroni
K, Chiusolo P, Casorelli I, et al. The risk
of recurrent deep venous thrombosis among heterozygous
carriers of both factor V Leiden and
the G20210A prothrombin mutation. N Engl J
Med. 1999; 341(11): 801-806.
35. Simone B, De Stefano V, Leoncini E, Zacho,
Martinelli I, Emmerich J, et al. Risk of venous
thromboembolism associated with single and
combined effects of factor V Leiden, prothrombin
20210A and methylenetetra-hydrofolate reductase
C677T: A meta-analysis involving over
11,000 cases and 21,000 controls. Eur J Epidemiol.
2013; 28(8): 621-647.
|
|
|
|
|
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|